Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20456344 | 0.87 | CHRM2 (0.37) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL1401215 | 0.85 | BUB1 (0.37) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL6921819 | 0.84 | CHRM2 (0.35) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL3376811 | 0.81 | BUB1 (0.39) | CHRM2CHRM1CHRM3BUB1CTSK | |
| SCHEMBL6783662 | 0.80 | BUB1 (0.34) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL9948965 | 0.80 | USP2 (0.44) | DDB1CRBNUSP2SMN1; SMN2HPGD | |
| SCHEMBL426520 | 0.80 | BUB1 (0.34) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL6922466 | 0.79 | CHRM2 (0.32) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL29348855 | 0.78 | USP2 (0.38) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL6921988 | 0.78 | CRBN (0.35) | CHRM2CHRM1CHRM3DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | CHRM2 3674/4885CHRM1 2219/4885CHRM3 3265/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 3673/4885CHRM1 2349/4885CHRM3 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.